Stem Cell Agency Plan Falls Far Short of Solving IOM Concerns
The governing board of the $3 billion California stem cell agency last week fell far short of complying with the recommendations of a blue-ribbon Institute of Medicine (IOM) study that the agency itself commissioned to improve its performance.
Many of the proposals by the IOM dealt with conflicts of interest at the eight-year-old agency, which board memb…
Keep reading with a 7-day free trial
Subscribe to The California Stem Cell Report to keep reading this post and get 7 days of free access to the full post archives.